TrialBMC medicine2025

The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial.

Bing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.